REGULATORY

Japan OK for MSD’s 9-Valent HPV Vaccine Could Be Delayed after Deluge of Comments Hit Proposed Rule Changes

June 26, 2020
Japanese approval for MSD’s nine-valent HPV vaccine could be delayed beyond the originally expected June period after a flood of public comments were sent in for proposed revisions to associated rules, it has been learned. The nine-valent vaccine has been…

To read the full story

Related Article

REGULATORY

Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…

By Hayate Horiguchi

Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…

By Philip Carrigan

We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…